Followers | 207 |
Posts | 19933 |
Boards Moderated | 5 |
Alias Born | 01/09/2019 |
Wednesday, November 24, 2021 10:16:34 AM
Everything I say is my educated opinion and is NOT investment advice
Recent KTTA News
- Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 05/28/2024 10:59:00 AM
- Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 04/29/2024 11:59:00 AM
- Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers • GlobeNewswire Inc. • 04/24/2024 11:59:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 02:46:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 02:46:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 02:45:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 02:45:23 AM
- Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 • GlobeNewswire Inc. • 02/13/2024 12:59:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:30:41 PM
- Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position • GlobeNewswire Inc. • 01/08/2024 12:59:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:47:43 PM
- Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients • GlobeNewswire Inc. • 01/02/2024 01:35:05 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/28/2023 10:00:30 PM
- Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023 • GlobeNewswire Inc. • 12/28/2023 10:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 04:30:10 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/19/2023 10:26:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 10:21:07 PM
- Pasithea Therapeutics Announces Results from 2023 Annual Meeting • GlobeNewswire Inc. • 12/19/2023 10:19:00 PM
- Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models • GlobeNewswire Inc. • 12/11/2023 01:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/29/2023 10:00:00 PM
- Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders • GlobeNewswire Inc. • 11/29/2023 09:27:00 PM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM